C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,331 | -70.1% | 1,791 | -55.7% | 0.00% | – |
| Q2 2023 | $11,129 | +5174.4% | 4,047 | -94.0% | 0.00% | – |
| Q1 2023 | $211 | -44.3% | 67,088 | +4.3% | 0.00% | -100.0% |
| Q4 2022 | $379 | -99.9% | 64,302 | +0.4% | 0.00% | 0.0% |
| Q3 2022 | $562,000 | +24.1% | 64,033 | +6.6% | 0.00% | 0.0% |
| Q2 2022 | $453,000 | -54.1% | 60,052 | +47.6% | 0.00% | 0.0% |
| Q1 2022 | $987,000 | -19.9% | 40,699 | +6.3% | 0.00% | -50.0% |
| Q4 2021 | $1,232,000 | -27.8% | 38,276 | +0.2% | 0.00% | 0.0% |
| Q3 2021 | $1,707,000 | +30.5% | 38,195 | +10.5% | 0.00% | 0.0% |
| Q2 2021 | $1,308,000 | +244.2% | 34,565 | +236.2% | 0.00% | +100.0% |
| Q1 2021 | $380,000 | +33.3% | 10,281 | +19.7% | 0.00% | – |
| Q4 2020 | $285,000 | – | 8,592 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |